Bioventus (BVS) EBIAT (2020 - 2026)

Bioventus (BVS) has 7 years of EBIAT data on file, last reported at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 218.05% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.0 million (up 196.88% YoY), and the FY2025 full-year result was $27.3 million, up 157.97% from the prior year.
• EBIAT for Q1 2026 stood at $3.1 million, down from $19.3 million in the prior quarter.
• Across five years, EBIAT topped out at $19.3 million in Q4 2025 and bottomed at -$100.0 million in Q2 2023.
• The 5-year median for EBIAT is -$6.1 million (2023), against an average of -$15.7 million.
• The widest annual swing landed in 2022, when EBIAT slumped 3109.92%; it then soared 3300.17% in 2025.
• A 5-year view of EBIAT shows it stood at -$44.9 million in 2022, then surged by 86.41% to -$6.1 million in 2023, then surged by 90.11% to -$603000.0 in 2024, then jumped by 3300.17% to $19.3 million in 2025, then sank by 83.87% to $3.1 million in 2026.
• The last three EBIAT figures came in at $3.1 million (Q1 2026), $19.3 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.

Peer Comparison